New perspectives on rare connective tissue calcifying diseases

Nabil A Rashdan, Frank Rutsch, Hervé Kempf, András Váradi, Georges Lefthériotis, Vicky E Macrae

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Connective tissue calcifying diseases (CTCs) are characterized by abnormal calcium deposition in connective tissues. CTCs are caused by multiple factors including chronic diseases (Type II diabetes mellitus, chronic kidney disease), the use of pharmaceuticals (e.g. warfarin, glucocorticoids) and inherited rare genetic diseases such as pseudoxanthoma elasticum (PXE), generalized arterial calcification in infancy (GACI) and Keutel syndrome (KTLS). This review explores our current knowledge of these rare inherited CTCs, and highlights the most promising avenues for pharmaceutical intervention. Advancing our understanding of rare inherited forms of CTC is not only essential for the development of therapeutic strategies for patients suffering from these diseases, but also fundamental to delineating the mechanisms underpinning acquired chronic forms of CTC.
Original languageEnglish
Pages (from-to)14-23
JournalCurrent Opinion in Pharmacology
Early online date27 Feb 2016
Publication statusPublished - 1 Jun 2016


Dive into the research topics of 'New perspectives on rare connective tissue calcifying diseases'. Together they form a unique fingerprint.

Cite this